Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DIOVAN HCT vs ALDORIL D30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Valsartan is an angiotensin II receptor blocker (ARB) that selectively blocks the binding of angiotensin II to the AT1 receptor, causing vasodilation and reduced aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride cotransporter in the distal convoluted tubule, increasing excretion of sodium and water.
Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.
Hypertension (FDA-approved),Heart failure (off-label, valsartan component),Post-myocardial infarction (off-label, valsartan component)
Hypertension
One tablet orally once daily. Available strengths: 80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg, 320 mg/12.5 mg, 320 mg/25 mg. Titrate to blood pressure response; maximum dose 320 mg/25 mg daily.
Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.
Valsartan: 6 hours; hydrochlorothiazide: 6–15 hours (mean 9.6 hours). Clinical context: allows once-daily dosing; half-life prolonged in renal impairment.
Terminal elimination half-life of hydrochlorothiazide is 6-15 hours; methyldopa half-life is 1.8 hours (normal renal function). In renal impairment, half-life of both components is prolonged.
Valsartan is primarily metabolized by CYP2C9 (minor) and eliminated unchanged in bile and urine. Hydrochlorothiazide is not extensively metabolized and is excreted unchanged in urine.
Methyldopa is metabolized by conjugation (catechol-O-methyltransferase) and hepatic sulfation; hydrochlorothiazide is not extensively metabolized and is excreted unchanged by the kidney.
Valsartan: primarily biliary (83%) and renal (13%) as unchanged drug; hydrochlorothiazide: renal (≥95%) as unchanged drug.
Renal: approximately 50% as parent drug and metabolites; biliary/fecal: minimal, less than 5%.
Valsartan: 94–97% (primarily albumin); hydrochlorothiazide: 68% (albumin).
Methyldopa: <10% bound to plasma proteins; hydrochlorothiazide: 40-68% bound to albumin.
Valsartan: 17 L (≈0.24 L/kg for 70 kg); hydrochlorothiazide: 3.6–7.8 L/kg (≈0.5–1.1 L/kg). Clinical meaning: Valsartan distributes mainly in plasma; HCTZ widely distributed into tissues.
Methyldopa: Vd 0.2-0.3 L/kg (distributes into tissues, crosses placenta); hydrochlorothiazide: Vd 0.75-1.5 L/kg (extensively distributed, does not cross blood-brain barrier significantly).
Valsartan: 25% (oral, with food reduces absorption by 40%); hydrochlorothiazide: 65–75% (oral).
Oral bioavailability of methyldopa is approximately 25% (variable, influenced by gut metabolism); hydrochlorothiazide bioavailability is 65-75%.
Contraindicated in anuria. For GFR 30-60 m L/min, use cautiously; consider lower starting doses. GFR <30 m L/min: not recommended due to thiazide component.
GFR 30-60 m L/min: reduce dose by 50%; GFR <30 m L/min: not recommended.
Child-Pugh A: no adjustment. Child-Pugh B: use caution; valsartan exposure increases significantly. Child-Pugh C: avoid use.
Child-Pugh Class B or C: contraindicated; use not recommended.
Not approved for pediatric patients; safety and efficacy not established.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
No initial dose adjustment required, but consider lower starting doses due to greater sensitivity to antihypertensive effects; monitor renal function and electrolytes.
Start with lowest dose; monitor for hypotension, electrolyte imbalance, and CNS effects; consider reduced initial dose.
None.
None
Fetal toxicity: avoid use during pregnancy; can cause oligohydramnios and fetal renal dysfunction.,Hypotension in volume-depleted patients.,Electrolyte imbalances (e.g., hypokalemia, hyponatremia) due to thiazide component.,Renal impairment: monitor renal function; may exacerbate in bilateral renal artery stenosis.,Acute angle-closure glaucoma (thiazide component).,Sulfonamide allergy (cross-reactivity with thiazide).,Exacerbation of lupus erythematosus.
May cause hemolytic anemia, liver disorders, positive Coombs test, sedation, depression, and hypersensitivity reactions. Hydrochlorothiazide may cause electrolyte imbalance, hyperuricemia, photosensitivity, and exacerbation of systemic lupus erythematosus. Use with caution in renal impairment, hepatic disease, and in patients with a history of drug-induced hemolytic anemia.
Anuria,Hypersensitivity to valsartan, hydrochlorothiazide, or sulfonamide-derived drugs,Pregnancy (second and third trimesters),Severe hepatic impairment (Child-Pugh class C),Concomitant use with aliskiren in patients with diabetes mellitus or renal impairment (GFR <60 m L/min)
Active hepatic disease, history of previous methyldopa therapy-associated liver disorders; anuria; hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamide-derived drugs.
Avoid grapefruit juice as it may alter drug metabolism. Limit high-potassium foods (e.g., bananas, oranges, potatoes, spinach) if potassium levels rise. Reduce sodium intake (less than 2 g/day) to enhance antihypertensive effect. Avoid excessive alcohol consumption. Maintain adequate fluid intake to prevent dehydration.
Food may decrease absorption of methyldopa. Avoid excessive intake of high-potassium foods (e.g., bananas, oranges) unless directed. Hydrochlorothiazide may cause potassium depletion; maintain adequate dietary potassium. Avoid natural licorice as it can worsen hypokalemia.
First trimester: Potential risk based on mechanism (angiotensin II receptor blockade and thiazide diuretic); second and third trimesters: Known fetal toxicity including oligohydramnios, fetal renal dysfunction, skull ossification defects, and neonatal hypotension; avoid in pregnancy, especially after 20 weeks gestation.
First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; possible fetal bradycardia and neonatal hypotension. Hydrochlorothiazide may cause fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances.
The active metabolites hydrochlorothiazide is excreted in low amounts in breast milk; low M/P ratio of approximately 0.25; valsartan excretion unknown; because of potential adverse effects on the nursing infant, especially renal effects, use is not recommended; alternative therapies are preferred.
Methyldopa is excreted in breast milk in low concentrations; M/P ratio approximately 0.2. Hydrochlorothiazide is excreted in minimal amounts; may suppress lactation. Consider risks versus benefits.
Dose adjustments are not applicable as DIOVAN HCT is contraindicated in pregnancy; exposure should be avoided; if required, consider switching to an alternative antihypertensive with a safer profile during pregnancy.
Methyldopa: Pregnancy-induced plasma volume expansion may require dose titration; monitor blood pressure and adjust accordingly. Hydrochlorothiazide: Often avoided in pregnancy due to volume depletion risks; if used, monitor electrolytes and renal function, no pharmacokinetic data necessitate routine dose adjustment.
Diovan HCT combines valsartan (ARB) and hydrochlorothiazide (thiazide diuretic). Monitor renal function, electrolytes (especially potassium and sodium), and blood pressure. Avoid use in pregnancy; contraindicated in anuria and severe renal impairment. Use caution in patients with pre-existing electrolyte imbalances, diabetes, or history of gout. May cause hyperkalemia with valsartan and hypokalemia with HCTZ; net effect requires monitoring. Onset of action within 2 hours, peak effect at 4-6 hours. Not recommended for initial therapy; titrate from individual components.
ALDORIL D30 combines methyldopa (central alpha-2 agonist) and hydrochlorothiazide (thiazide diuretic). Monitor for orthostatic hypotension, especially at initiation. Taper not needed for methyldopa but discontinue if fever or liver dysfunction occurs. Interferes with urinary catecholamine measurements (false elevation). Hydrochlorothiazide may cause hyponatremia, hypokalemia, and hyperglycemia; check electrolytes and glucose periodically.
Take exactly as prescribed, usually once daily. Do not skip doses.,Avoid potassium supplements or salt substitutes without doctor approval.,Report symptoms of electrolyte imbalance: muscle cramps, weakness, irregular heartbeat, excessive thirst.,May cause dizziness or lightheadedness; avoid driving until you know how it affects you.,This medication can make you urinate more frequently; take in the morning to minimize nighttime urination.,Avoid alcohol, which can increase dizziness and blood pressure lowering effects.,Notify your doctor if you become pregnant or plan to become pregnant; this drug can harm the fetus.,Stay hydrated, especially in hot weather or during exercise, to prevent dehydration.,Tell your doctor about all other medications, especially NSAIDs, lithium, and other blood pressure drugs.,Do not stop taking without consulting your doctor; sudden discontinuation may worsen blood pressure.
Take exactly as prescribed, preferably with food to reduce stomach upset.,Rise slowly from sitting or lying down to prevent dizziness.,This drug may make you drowsy; avoid driving or operating machinery until you know how it affects you.,Report fever, unexplained fatigue, jaundice, or dark urine immediately.,Weigh yourself daily and report rapid weight gain or swelling.,Limit alcohol intake as it can increase side effects.,Do not use salt substitutes containing potassium without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DIOVAN HCT vs ALDORIL D30, answered by our medical review team.
DIOVAN HCT is a Antihypertensive Combination that works by Valsartan is an angiotensin II receptor blocker (ARB) that selectively blocks the binding of angiotensin II to the AT1 receptor, causing vasodilation and reduced aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride cotransporter in the distal convoluted tubule, increasing excretion of sodium and water.. ALDORIL D30 is a Antihypertensive Combination that works by Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DIOVAN HCT and ALDORIL D30 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DIOVAN HCT is: One tablet orally once daily. Available strengths: 80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg, 320 mg/12.5 mg, 320 mg/25 mg. Titrate to blood pressure response; maximum dose 320 mg/25 mg daily.. The standard adult dose of ALDORIL D30 is: Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DIOVAN HCT and ALDORIL D30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DIOVAN HCT is classified as Category C. First trimester: Potential risk based on mechanism (angiotensin II receptor blockade and thiazide diuretic); second and third trimesters: Known fetal toxicity including oligohydram. ALDORIL D30 is classified as Category C. First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; p. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.